Novartis loses panel appeal
India’s Intellectual Property Appellate Board (IPAB) has dismissed Novartis’s objection to the presence of former patent office head S Chandrasekaran on the panel deciding on the patentability of Glivec
Novartis is unhappy with the choice of Chandrasekaran because he was controller general of Indias patent office at the time that its patent for the blockbuster cancer treating drug Givec was rejected. Chandrasekaran...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.